Additionally, we discovered that AKT1 is the predominant kinase contributing to DAV resistance in AML, and its inhibition effectively overcame the unsatisfactory anti‐leukemic activity and induced robust cell death when combined with DAV treatment. This evidence concerns the gene AKT1 and acute myeloid leukemia.